New data and considerations for EGFR+ NSCLC management in 2022

Learning objective:         

After watching this broadcast, participants should be able to:

• Discuss new data on the management of patients with EGFR-mutant NSCLC
• Evaluate how new data on therapeutic options for EGFR exon 20 insertion mutations in NSCLC will be integrated into clinical practice

 

Scientific Committee:

• Matthew Krebs (UK)
• Antonio Passaro (Italy)

Faculty:

• Natasha Leighl (Canada)
• Alfredo Addeo (Switserland)

 

Claim your CPD credits

The content of the following has been certified by the CPD Certification Service as conforming to continuing professional development principles.

You can claim 1 credit for this activity.

Please make a note of the below information to claim your points.

Name of activity: Janssen Oncology Medical Education Webinar (OME) Post ELCC: New data and considerations for EGFR+ NSCLC management in 2022

Certificate number: A032749

Date of activity: April 2022

Provider: Sciterion 013096